Loading stock data…
Loading stock data…
US$0.06
Get one email when PVCT crosses your level. Checked every 15 minutes during market hours.
▼ -0.00 (-0.63%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
44.3
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.00
Bearish momentumMACD below its signal line (0.00).
50-day average
0.07
Price belowShort-term trend reference.
200-day average
0.06
Price aboveLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the research and development of immune-system directed treatments. The company's primary goal is to harness the body's natural defense mechanisms to combat cancer, inflammation, and infectious diseases. Provectus's flagship product, PV-10, is an investigational oncology drug derived from Rose Bengal, which is designed to target and destroy cancerous tumors while stimulating a systemic immune response a…
www.provectusbio.com| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-04-29 | 3.69 | 4.1 | ✓ Beat |
| 2021-03-01 | — | -0.01 | — |
| 2020-03-04 | — | -0.02 | — |
| 2019-11-11 | — | -0.24 | — |
| 2019-08-07 | — | -0.01 | — |
| 2018-05-08 | — | -0.01 | — |
| 2018-03-22 | — | -0.01 | — |
| 2017-11-07 | — | -0.01 | — |
Companies in the same industry, via Finnhub